Big-caps join the coronavirus scramble
It is no longer just small biotechs that are taking aim at coronavirus: Gilead Sciences and Glaxosmithkline are getting involved too, albeit via different routes.
Go or no go? Esperion's double whammy and a look to priority reviews
Four assets with previous rejections are due FDA decisions in February, while those with priority review could become the next string of early approvals.
Acceleron’s post-Reblozyl plan comes together
Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.
Astra and Acasti throw the Amarin bulls more fodder
Amarin must hope that setbacks for Astrazeneca and Acasti show that in Vascepa it has the secret sauce.
Clinical win gives Verona a kiss of life
For Verona’s long-suffering shareholders today brought an unexpected clinical success with ensifentrine.
What makes a great year for takeovers?
The number of biopharma buyouts overall last year did not rise, though more deals were struck in the “sweet spot”, and premiums saw a healthy rise.
Upcoming events – TG's long-awaited outcome and Insmed's mid-stage lung data
After making investors wait more than a year, TG Therapeutics is gearing up to release results of its lead leukaemia combo, while Insmed hopes to succeed in a very tricky…
Glaxo’s myeloma Dreamm turns into a nightmare
Belantamab’s registrational Dreamm-2 study comes up short of an earlier trial and, more importantly, now seriously lags competitors’ data.
Ash 2019 – for Car-T the bispecific antibody threat is real
As numerous Car-T therapies battle it out in the burgeoning BCMA field, Ash shows that the real threat could come from elsewhere.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.